Summary of integrative structure determination of Structure of human myr-Arf1-GTP bound to MSPdH5 nanodisc (PDB ID: 9A8S | pdb_00009a8s)

1. Model Composition	
1.1. Entry composition	- Membrane Scaffold Protein (MSP) Apolipoprotein A-I: chain(s) A, B (167 residues) - [(2R)-2-[(E)-octadec-9-enoyl]oxy-3-[oxidanyl-[(1R,2R,3S,4R,5R,6S)-2,3,6-tris(oxidanyl)-4,5-diphosphonooxy-cyclohexyl]oxy-phosphoryl]oxy-propyl] (E)-octadec-9-enoate: chain(s) AD [A], AF [A], AU [B], AV [B], AX [P], AY [P] - [(2R)-2-[(E)-octadec-9-enoyl]oxy-3-[oxidanyl-[(1R,2R,3S,4R,5R,6S)-2,3,6-tris(oxidanyl)-4,5-diphosphonooxy-cyclohexyl]oxy-phosphoryl]oxy-propyl] (E)-octadec-9-enoate: chain(s) AU [B], BE [A], BF [B], BG [B], BH [B], BJ [P], BK [P] - ADP-ribosylation factor 1: chain(s) C [P] (180 residues) - 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine: chain(s) D [A], E [A], F [A], G [A], H [A], I [A], J [A], K [A], L [A], M [A], N [A], O [A], Q [A], R [A], S [A], T [A], U [A], V [A], W [A], X [A], Y [A], Z [A], AA [A], AC [B], BA [A], BB [B], BC [B], CA [A], CB [B], CC [B], DB [B], DC [P], EA [A], EB [B], EC [P], FA [A], FB [B], FC [P], GA [A], GB [B], GC [P], HA [A], HB [B], HC [P], IA [B], IB [B], IC [P], JA [B], JB [B], JC [P], KA [B], KB [B], KC [P], LA [B], LB [B], LC [P], MB [B], MC [P], NA [B], NB [B], NC [P], OA [B], OB [B], OC [P], PA [B], PB [B], PC [P], QA [B], QB [B], QC [P], RA [B], RB [B], RC [P], SA [B], SB [B], TA [B], TB [B], UA [B], UB [B], UC [P], VA [B], VB [B], VC [P], WA [B], WB [B], WC [P], XA [B], XC [P], YA [B], YB [B], YC [P], ZA [B], ZB [B] - 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine: chain(s) D [A], E [A], F [A], G [A], H [A], I [A], J [A], K [A], M [A], N [A], O [A], Q [A], R [A], S [A], T [A], V [A], W [A], X [A], Y [A], Z [A], AA [A], AE [A], AG [A], AH [A], AI [A], AJ [A], AK [A], AL [A], AM [A], AN [A], AO [A], AP [A], AQ [A], AR [A], AS [A], AT [B], AW [B], AZ [P], BA [A], BB [B], BD [P], CA [A], CB [B], DB [B], DC [P], EA [A], EB [B], EC [P], FA [A], FB [B], FC [P], GA [A], GB [B], GC [P], HA [A], HB [B], HC [P], IA [B], IB [B], IC [P], JA [B], JB [B], KA [B], KB [B], LA [B], LB [B], LC [P], MB [B], MC [P], NB [B], NC [P], OA [B], OB [B], OC [P], PA [B], PB [B], PC [P], QA [B], QB [B], QC [P], RA [B], RB [B], RC [P], SA [B], TA [B], UA [B], UC [P], VA [B], VC [P], WA [B], WC [P], XA [B], XC [P], YA [B] - 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine: chain(s) D [A], E [A], F [A], G [A], H [A], I [A], J [A], L [A], M [A], N [A], O [A], Q [A], R [A], S [A], T [A], U [A], V [A], W [A], X [A], Y [A], Z [A], AA [A], AE [A], AG [A], AT [B], AW [B], AZ [P], BA [A], BB [B], BD [P], BI [B], BL [P], BM [P], BN [P], BO [P], CA [A], CB [B], DC [P], EA [A], EB [B], EC [P], FA [A], FB [B], FC [P], GA [A], GB [B], GC [P], HA [A], HB [B], HC [P], IA [B], IB [B], IC [P], JA [B], JB [B], JC [P], KA [B], KB [B], KC [P], LA [B], LB [B], LC [P], MB [B], MC [P], NB [B], NC [P], OA [B], OB [B], OC [P], PA [B], PB [B], QA [B], QB [B], QC [P], RB [B], RC [P], SA [B], SB [B], TA [B], TB [B], UA [B], UB [B], UC [P],

	VA [B], VC [P], WA [B], WB [B], WC [P], XA [B], XC [P], YA [B], YB [B], ZA [B] - [(2R)-2-[(E)-octadec-9-enoyl]oxy-3-[oxidanyl-[(1R,2R,3S,4R,5R,6S)-2,3,6-tris(oxidanyl)-4,5-diphosphonooxy-cyclohexyl]oxy-phosphoryl]oxy-propyl] (E)-octadec-9-enoate: chain(s) P [A], AB [B], DA [A], MA [B], SC [P], TC [P], XB [B]
1.2. Datasets used for modeling	- NMR data, BMRB: <u>27726</u> - Experimental model, PDB: <u>pdb_00003lvq</u> - NMR data, BMRbig: <u>BMRbig101</u> - Experimental model, PDB: <u>pdb_00002n5e</u> - Experimental model, PDB: <u>pdb_00002ksq</u> - Comparative model, Not available
2. Representation	
2.1. Number of representations	3
2.2. Scale	- Atomic - Atomic - Atomic
2.3. Number of rigid and flexible segments	- 0, 3 - 0, 3 - 0, 3
3. Restraints	
3.1. Physical principles	Information about physical principles was not provided
3.2. Experimental data	
4. Validation	
4.2. Number of ensembles	0
4.3. Number of models in ensembles	Not applicable
4.4. Number of deposited models	3
4.5. Model precision	Not available
4.6. Data quality	Data quality has not been assessed
4.7. Model quality: assessment of atomic segments	- Clashscore: 0.00-0.00 - Ramachandran outliers: 3-6 - Sidechain outliers: 35-38
4.8. Fit to data used for modeling	Fit of model to information used to compute it has not been determined
4.9. Fit to data used for validation	Fit of model to information not used to compute it has not been determined
5. Methodology and Software	

1. 5.1. Method name	Not available
5.3. Method description	NAMD multi-state modeling
2. 5.1. Method name	Not available
5.3. Method description	NAMD multi-state modeling
3. 5.1. Method name	Not available
5.3. Method description	NAMD multi-state modeling
5.5. Software	- NAMD2 (version Not available) - CHARMM-GUI (version Not available) - Swiss-Model (version Not available) - Visual Molecular Dynamics (VMD) (version Not available)